Search research articles
Contact Us
Filters
Showing results (81-90 of 120) with videos related to
Page
of 12
Sort By:
Cancer Treatment Reviews
|
March 18, 2017
Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives
Ioana Lambrescu, Simona Fica, Diana Martins, et al.
Journal of Neuroendocrinology
|
April 14, 2026
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE: A post-authorisation safety study
Johannes Hofland, Chiara Maria Grana, Martin O Weickert, et al.
Neuroendocrinology
|
March 5, 2016
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione, Patrick Maisonneuve, Francesca Spada, et al.
JAMA Network Open
|
February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
Chiara A Cella, Maren Knoedler, Marcia Hall, et al.
Cancers
|
September 23, 2022
Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes
Chiara Alessandra Cella, Francesca Spada, Alfredo Berruti, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Neuroendocrinology
|
August 31, 2022
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study
Piero Ferolla, Alfredo Berruti, Francesca Spada, et al.
Neuroendocrinology
|
January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Endocrine-Related Cancer
|
July 10, 2023
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix
Carmine Valenza, Francesca Spada, Francesco Multinu, et al.
BMC Cancer
|
November 12, 2025
Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021)
Angela Damato, Giuseppe Maglietta, Lorenzo Antonuzzo, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 120) with videos related to
Sort By:
Page
of 12
Cancer Treatment Reviews
|
March 18, 2017
Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives
Ioana Lambrescu, Simona Fica, Diana Martins, et al.
Journal of Neuroendocrinology
|
April 14, 2026
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE: A post-authorisation safety study
Johannes Hofland, Chiara Maria Grana, Martin O Weickert, et al.
Neuroendocrinology
|
March 5, 2016
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione, Patrick Maisonneuve, Francesca Spada, et al.
JAMA Network Open
|
February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer
Chiara A Cella, Maren Knoedler, Marcia Hall, et al.
Cancers
|
September 23, 2022
Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes
Chiara Alessandra Cella, Francesca Spada, Alfredo Berruti, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Neuroendocrinology
|
August 31, 2022
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study
Piero Ferolla, Alfredo Berruti, Francesca Spada, et al.
Neuroendocrinology
|
January 21, 2016
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, et al.
Endocrine-Related Cancer
|
July 10, 2023
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix
Carmine Valenza, Francesca Spada, Francesco Multinu, et al.
BMC Cancer
|
November 12, 2025
Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021)
Angela Damato, Giuseppe Maglietta, Lorenzo Antonuzzo, et al.
Page
of 12